Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030567 (Parkinson's disease)
 63,064 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The efficacy and safety of ropinirole, a novel nonergot dopamine D2-like receptor agonist, was assessed as monotherapy for the treatment of patients with early-stage Parkinson's disease. In this double-blind, multicenter trial, patients were randomly allocated in a ratio of 2:1 to receive, over a 12-week period, either ropinirole or placebo. Clinical status was assessed using the Unified Parkinson's Disease Rating Scale (UP-DRS), Clinician's Global Evaluation (CGE), and a finger-tapping score. In all, 41 patients received ropinirole and 22 received placebo. The end-point analysis, on an intention-to-treat basis, revealed a significant difference (p = 0.018) in improvement in UP-DRS motor score from baseline between treatment groups (ropinirole, 43.4%; and placebo, 21.0%). Other parameters, including the number of responders and improvement in CGE, showed similar results. Three patients in the ropinirole group and one patient in the placebo group discontinued the study because of adverse events. There was no significant difference between the treatment groups in the overall incidence of adverse events. Although the dopaminergic side effects were reported significantly more frequently in the ropinirole group than in the placebo group (dizziness, p = 0.0326; nausea, p = 0.001; and somnolence, p = 0.005), none necessitated study withdrawal. There was no evidence of any chronic effect of the study medication on vital signs. In conclusion, ropinirole is a safe and well-tolerated drug and, as monotherapy, provided significant therapeutic benefit compared with placebo to patients in the early stages of Parkinson's disease.
 ...
PMID:A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. 957 96

In seven women and two men with Parkinson's disease, Hoehn and Yahr stage 1 or 2, the effect of repetitive transcranial magnetic stimulation (rTMS) was evaluated. Primary endpoint outcome measure was the changing of the motor items of the Unified Parkinson's Disease Rating Scale (subscale III of UP-DRS) 24 h after stimulation. Kinesiologic tests and writing samples were secondary outcome measures. After discontinuing all medication, stimulation was performed with 5 Hz at 90% of the motor threshold over the primary motor cortex of the more affected. There were 2250 stimuli applied, divided into 15 trains at intervals of 10 s. The identical treatment of the opposite side served as control treatment. Only treatment of the more affected side resulted in a significant improvement of the clinical symptoms of 46% as assessed by the UPDRS (p < 0.02). This effectiveness differed significantly from the control treatment (21%, p < 0.02). The kinesiological testing did not show any significant speeding of movements (p > 0.05). Some patients showed a normalisation of the previously disturbed handwriting specimen. These data confirm the previous observation that rTMS of primary motor regions leads to at least temporary clinical improvement of symptoms in patients with Parkinson's disease.
 ...
PMID:[Contralateral and ipsilateral repetitive transcranial magnetic stimulation in Parkinson patients]. 1178 38

Urinary dysfunction in idiopathic Parkinson's disease (IPD) has already been described, however its incidence, urodynamic pattern, dependence on the severity of parkinsonism as well as improvement with levodopa treatment are not exactly known. The aim of the study was to evaluate the frequency of urinary disturbances in patients with idiopathic Parkinson's disease and their relationship to treatment with levodopa. The investigation was carried out on 41 IPD patients aged 37-84 (mean 61.6) years. The neurological examination, including evaluation of parkinsonism according to UP-DRS scale was conducted together with the urological tests, including uroflowmetry and cystometry. Patients with infection of the urinary tract and with prostate hypertrophy were excluded from the study. 32 (78%) patients had urinary symptoms: frequency in 27 cases (65%), urgency in 9 cases (21%), urge incontinence in 1 case and dysuria in 1 case. Disorders in urodynamic examination were found in 26 cases (63%); they were: detrusor hyperactivity in 21 cases (51%), prolonged time of micturition in 18 cases (44%) and decrease of maximum flow rate in 19 cases (46%). Detrusor hyperactivity was more frequent in patients with extended parkinsonian motor signs. The results of the examination indicate frequent urinary disturbances (70%) in IPD, which improve during treatment with increased dose of levodopa.
 ...
PMID:[Micturition disturbances in Parkinson's disease. Clinical and urodynamic evaluation]. 1205 13

Clinical and neuroimaging studies have shown that verb processing suggests a preferential participation of a prefrontal network, which is dysfunctional in Parkinson's disease (PD). To assess a verb processing deficit in PD, we compared noun- and verb-generation tasks for 34 nondemented PD patients (according to the Dementia Rating Scale) with 34 matched normal subjects, using two intracategory tasks (noun/noun and verb/verb generation) and two intercategory tasks (noun/verb and verb/noun generation). PD patients were significantly impaired in the two tasks involving verb production, i.e., verb/verb and noun/verb generation, whereas their performance was similar to those of controls in the two tasks requiring noun production. For the two impaired tasks, we assessed 1) the influence of lexical competition that corresponds to the presence of several candidate words for a given stimulus; 2) the influence of slight cognitive dysfunction; and 3) the influence of motor deficit. Significant correlations were found between DRS scores and performance on the noun/verb task, and no significant correlations were found between lexical competition or motor deficit and performance. The specific deficit for verb production in PD patients is discussed in relation to deficits affecting either action or grammatical representations.
 ...
PMID:Deficit of verb generation in nondemented patients with Parkinson's disease. 1253 7

This study examined qualitative aspects of phonemic and semantic fluency before and after unilateral pallidotomy in patients with intractable Parkinson's Disease (PD). Specifically, clustering (number of similar words generated sequentially) and switching (number of changes or switches from one cluster to another) were evaluated for both fluency tasks. Twenty-five PD patients participated and were grouped according to whether they improved or declined on each of the fluency measures after surgery. Decliners evidenced decreased switching, but not clustering, suggesting difficulties with set-shifting and cognitive flexibility rather than a diminished semantic store of information or retrieval difficulties. Though consistent with hypotheses about difficulties with executive processing after pallidotomy, a series of correlational analyses with composite measures of neuropsychological functioning (attention, language, executive processing, and memory) suggest caution in interpreting these findings. In these analyses, clustering was not meaningfully related to any of the composites whereas switching was significantly and positively related to the composites; this pattern emerged, for the most part, on both fluency measures before and after surgery. Switching, but not clustering, was also significantly and positively correlated with total words generated on both semantic and phonemic fluency. Switching changes across time were also related to DRS changes post-pallidotomy. These correlational analyses challenge the specificity of the switching variable and, more broadly, the validity of these qualitative measures of verbal fluency.
 ...
PMID:Qualitative analysis of verbal fluency before and after unilateral pallidotomy. 1470 83

We studied the relationship between two screening cognitive measures and off motor Unified Parkinson's Disease Rating Scale (UPDRS) scores in 108 Parkinson's disease patients. Multiple regressions were conducted to examine the UPDRS subscores' unique contributions to cognitive function. When including bradykinesia, rigidity, and postural/gait instability subscores, only bradykinesia predicted Mini Mental Status Examination (MMSE), normalized beta = -0.57, t(104) = -3.31, P < 0.01, and Dementia Rating Scale-2 (DRS-2), normalized beta = -0.45, t(104) = -2.55, P < 0.05. Tremor was not included in the regression analyses because it did not correlate with cognitive function. When including axial and appendicular subscores, only the axial subscore predicted MMSE, normalized beta = -0.39, t(105) = -3.19, P < 0.01, and DRS-2 scores, normalized beta = -0.40, t(106) = -3.28, P < 0.01. When including left-sided and right-sided subscores, only the right-sided symptoms predicted DRS-2 scores, normalized beta = -0.28, t(105) = -2.45, P < 0.05, and showed a trend toward predicting MMSE scores, normalized beta = -0.22, t(105) = -1.95, P = 0.054. We therefore found that right-sided symptoms (for laterality), axial symptoms (for region), and bradykinesia (for type of symptoms) were the best predictors of cognitive function.
 ...
PMID:Laterality, region, and type of motor dysfunction correlate with cognitive impairment in Parkinson's disease. 1708 86

Patients with Parkinson's disease (PD) often have cognitive deficits from the time of diagnosis. Except in patients with dementia, the impact of cognitive symptoms on daily function is not well documented. This study had two objectives: (1) to determine the functional significance of cognitive deficits in nondemented patients with PD and (2) to assess the sensitivity of two measures of global cognitive abilities to identify individuals with impaired ADL function. One hundred eleven subjects with PD and a range of cognitive abilities were included. Of these, 20 were diagnosed with PDD. All subjects were assessed with the Mattis Dementia Rating Scale to two (DRS-2) and the Mini-Mental State Examination (MMSE). ADL function was reported by an informant using the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL). The ability of the DRS-2 and MMSE to capture the impact of cognitive impairment on ADL function was assessed in the entire cohort and in subsets of nondemented individuals. After adjustment for covariates, cognition as measured by the DRS-2 was strongly related to ADL function in the entire cohort (partial correlation coefficient = 0.55, P < 0.001). The association remained strong when only nondemented subjects were included (r = 0.42, P < 0.001). The DRS-2 was significantly more accurate than the MMSE, particularly for detecting milder degrees of ADL impairment (ROC area = 0.87 vs. 0.75, P = 0.0008). Cognition is associated with impairment in ADL function, even in nondemented patients with PD. However, sensitive cognitive assessment measures may be needed to identify these functionally relevant impairments.
 ...
PMID:Association between cognition and function in patients with Parkinson disease with and without dementia. 2031 53

We present a novel approach to transcranial B-mode sonography for Parkinson's disease (PD) diagnosis by using 3-D ultrasound (3-DUS). We reconstructed bilateral 3-DUS volumes of the midbrain and substantia nigra echogenicities (SNE) and report results of a more objective abnormality detection in (PD). For classification, we analyzed volumetric measurements of midbrain and SNE in subjects with PD and healthy controls (HC). After blinded segmentation of these structures in 22/23 subjects (11 PD, 11 HC) and by two observers with varying prior experience in this technique, the classification algorithm yielded up to 91% sensitivity and 64% specificity using the larger volume of both SNE as a single-dimensional features and up to 90.9% sensitivity and 72.7% specificity using a multidimensional feature set with midbrain and both SNE volumes. This pilot study indicates that our TC-3-D-US approach is technically feasible and less dependent on the investigator's experience and good bone windows. Our pilot study yielded a fairly high sensitivity and specificity in differentiating between subjects with PD and HC.
 ...
PMID:Three-dimensional sonographic examination of the midbrain for computer-aided diagnosis of movement disorders. 2319 1

Cognitive impairment is one of the earliest, most common, and most disabling non-motor symptoms in Parkinson's disease (PD). Thus, routine screening of global cognitive abilities is important for the optimal management of PD patients. Few global cognitive screening instruments have been developed for or validated in PD patients. The Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Dementia Rating Scale-2 (DRS-2) have been used extensively for cognitive screening in both clinical and research settings. Determining how to convert the scores between instruments would facilitate the longitudinal assessment of cognition in clinical settings and the comparison and synthesis of cognitive data in multicenter and longitudinal cohort studies. The primary aim of this study was to apply a simple and reliable algorithm for the conversion of MoCA to MMSE scores in PD patients. A secondary aim was to apply this algorithm for the conversion of DRS-2 to both MMSE and MoCA scores. The cognitive performance of a convenience sample of 360 patients with idiopathic PD was assessed by at least two of these cognitive screening instruments. We then developed conversion scores between the MMSE, MoCA, and DRS-2 using equipercentile equating and log-linear smoothing. The conversion score tables reported here enable direct and easy comparison of three routinely used cognitive screening assessments in PD patients.
 ...
PMID:Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. 2622 96